B-cell depletion in patients with multiple myeloma with the anti-CD20 monoclonal antibody rituximab after high dose therapy

被引：0
|
作者：
Witzens, M [1 ]
Gemmel, C [1 ]
Moos, M [1 ]
Goldschmidt, H [1 ]
Ho, AD [1 ]
机构：
[1] Univ Heidelberg, Dept Internal Med 4, D-69115 Heidelberg, Germany
来源：
BONE MARROW TRANSPLANTATION | 1999年 / 23卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
465
引用
收藏
页码：S141 / S141
页数：1
相关论文
共 50 条
  • [1] Anti-CD20 monoclonal antibody therapy in multiple myeloma
    Kapoor, Prashant
    Greipp, Patricia T.
    Morice, William G.
    Rajkumar, S. Vincent
    Witzig, Thomas E.
    Greipp, Philip R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (02) : 135 - 148
  • [2] Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma
    Heinzerling, L
    Dummer, R
    Kempf, W
    Schmid, MH
    Burg, G
    ARCHIVES OF DERMATOLOGY, 2000, 136 (03) : 374 - 378
  • [3] B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorders (PT-LPD).
    Grefer, J
    Oertel, SH
    Hummel, M
    Serke, S
    Reinke, P
    Jonas, S
    Anagnostopoulos, L
    Arnold, R
    Dörken, B
    Riess, H
    BLOOD, 2001, 98 (11) : 132A - 132A
  • [4] Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab
    Pickartz, T
    Ringel, F
    Wedde, M
    Renz, H
    Klein, A
    von Neuhoff, N
    Dreger, P
    Kreuzer, KA
    Schmidt, CA
    Srock, S
    Schoeler, D
    Schriever, F
    EXPERIMENTAL HEMATOLOGY, 2001, 29 (12) : 1410 - 1416
  • [5] Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis
    Fox, E.
    Steinman, L.
    Hartung, H.
    Alvarez, E.
    Qian, P.
    Wray, S.
    Robertson, D.
    Huang, D.
    Selmaj, K.
    Wynn, D.
    Weiss, M. S.
    Bosco, J. A.
    Power, S. A.
    Mok, K. A.
    Lee, L.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 68 - 68
  • [6] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    Arthritis Res Ther, 5
  • [7] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [8] T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma
    Vincent-Salomon, A
    Mathiot, C
    MacIntyre, E
    Girre, V
    Fourquet, A
    Mercier, C
    Fréneaux, P
    Dumont, J
    Decaudin, D
    LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 387 - +
  • [9] Monoclonal antibody therapy for B-Cell lymphoma: Clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan
    Tobinai, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (05) : 411 - 419
  • [10] Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan
    Kensei Tobinai
    International Journal of Hematology, 2002, 76 : 411 - 419
12345